🇺🇸 FDA
Patent

US 9132174

Treatment of heart disease by inhibition of the action of ribosomal S6 kinase 3 (RSK3)

granted A61KA61K31/519A61K31/7048

Quick answer

US patent 9132174 (Treatment of heart disease by inhibition of the action of ribosomal S6 kinase 3 (RSK3)) held by Anchored RSK3 Inhibitors, LLC expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Anchored RSK3 Inhibitors, LLC
Grant date
Tue Sep 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61K, A61K31/519, A61K31/7048, A61K31/713, A61K38/005